The glymphatic system and Amyotrophic lateral sclerosis
Research output: Contribution to journal › Review › Research › peer-review
Standard
The glymphatic system and Amyotrophic lateral sclerosis. / Eisen, Andrew; Nedergaard, Maiken; Gray, Emma; Kiernan, Matthew C.
In: Progress in Neurobiology, Vol. 234, 102571, 2024.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The glymphatic system and Amyotrophic lateral sclerosis
AU - Eisen, Andrew
AU - Nedergaard, Maiken
AU - Gray, Emma
AU - Kiernan, Matthew C.
N1 - Publisher Copyright: © 2024 Elsevier Ltd
PY - 2024
Y1 - 2024
N2 - The glymphatic system and the meningeal lymphatic vessels provide a pathway for transport of solutes and clearance of toxic material from the brain. Of specific relevance to ALS, this is applicable for TDP-43 and glutamate, both major elements in disease pathogenesis. Flow is propelled by arterial pulsation, respiration, posture, as well as the positioning and proportion of aquaporin-4 channels (AQP4). Non-REM slow wave sleep is the is key to glymphatic drainage which discontinues during wakefulness. In Parkinson's disease and Alzheimer's disease, sleep impairment is known to predate the development of characteristic clinical features by several years and is associated with progressive accumulation of toxic proteinaceous products. While sleep issues are well described in ALS, consideration of preclinical sleep impairment or the potential of a failing glymphatic system in ALS has rarely been considered. Here we review how the glymphatic system may impact ALS. Preclinical sleep impairment as an unrecognized major risk factor for ALS is considered, while potential therapeutic options to improve glymphatic flow are explored.
AB - The glymphatic system and the meningeal lymphatic vessels provide a pathway for transport of solutes and clearance of toxic material from the brain. Of specific relevance to ALS, this is applicable for TDP-43 and glutamate, both major elements in disease pathogenesis. Flow is propelled by arterial pulsation, respiration, posture, as well as the positioning and proportion of aquaporin-4 channels (AQP4). Non-REM slow wave sleep is the is key to glymphatic drainage which discontinues during wakefulness. In Parkinson's disease and Alzheimer's disease, sleep impairment is known to predate the development of characteristic clinical features by several years and is associated with progressive accumulation of toxic proteinaceous products. While sleep issues are well described in ALS, consideration of preclinical sleep impairment or the potential of a failing glymphatic system in ALS has rarely been considered. Here we review how the glymphatic system may impact ALS. Preclinical sleep impairment as an unrecognized major risk factor for ALS is considered, while potential therapeutic options to improve glymphatic flow are explored.
KW - Amyotrophic lateral sclerosis
KW - Epidemiology
KW - Glymphatic system
KW - Neurodegeneration
KW - Sleep
U2 - 10.1016/j.pneurobio.2024.102571
DO - 10.1016/j.pneurobio.2024.102571
M3 - Review
C2 - 38266701
AN - SCOPUS:85183475322
VL - 234
JO - Progress in Neurobiology
JF - Progress in Neurobiology
SN - 0301-0082
M1 - 102571
ER -
ID: 381888613